



**Wellpoint New Jersey**

P. O. Box 62509  
Virginia Beach, VA 24466-2509

<Date>

<Parent or Guardian of>

<Member Name>

<Member Address>

<Member City, State ZIP>

Dear Member or Parent/Guardian of <Member Name>:

We have important drug recall information about your prescription for Duloxetine Delayed-Release Capsules USP, 60 mg.

Our records show that you may have recently filled a prescription for this drug.

On May 6, 2026, the United States Food and Drug Administration (FDA) issued a Class II recall of one lot number of Duloxetine Delayed-Release Capsules USP, 60 mg.

Breckenridge Pharmaceutical, Inc. issued this recall due to CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit.

<p><b>Product:</b> Duloxetine Delayed-Release Capsules USP, 60 mg <b>NDC:</b> 51991-0748-90 <b>Lot number:</b> 241069C <b>Expiration date:</b> 05/31/2027</p>
---

Talk to your doctor before you stop taking any medication. Stopping a drug without a replacement could have health risks. Your doctor can talk to you about other options that are right for you.

**What you need to do next:**

Although the distributor doesn't need any action on your part, if you have questions or concerns about this recall, contact the distributor.

**[wellpoint.com/nj/medicaid](https://www.wellpoint.com/nj/medicaid)**

1091152NJMESWLP 05/26

OMHC# 078-25-59

105-CNMCD26062WLPNJ 051426



**We're here to help**

If you have questions about the recall, please call Breckenridge Pharmaceutical, Inc., the distributor, at 1-800-466-2700. You can contact the FDA toll-free at **888-INFO-FDA (888-463-6332)** or visit [fda.gov](http://fda.gov) for more information.

You can also call your doctor or pharmacist if you have questions about the drug or about this letter. If you have questions about your prescription drug benefits, please call Pharmacy Member Services at the phone number on your member ID card (TTY users can call **711**).

Sincerely,

Your Wellpoint service team

Enclosures: Language assistance sheet  
Nondiscrimination notice

This information is provided for educational purposes only and should not be considered medical advice. Talk to your physician for specific treatment options and recommendations best suited for you and before beginning any lifestyle program.



**Wellpoint New Jersey**

P. O. Box 62509  
Virginia Beach, VA 24466-2509

<Date>

<Padre o tutor de>

<Member Name>

<Member Address>

<Member City, State ZIP>

Estimado/a miembro o padre/tutor de <Member Name>:

Tenemos información importante del retiro de medicamento sobre su receta para cápsulas de liberación retardada de duloxetina, USP, 60 mg.

Nuestros registros muestran que usted tal vez ha surtido recientemente una receta de este medicamento.

El 6 de mayo de 2026, la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos emitió un retiro del mercado de Clase II de un número de lote de cápsulas de liberación retardada de duloxetina, USP, 60 mg.

Breckenridge Pharmaceutical, Inc. emitió este retiro debido a desviaciones en las Buenas Prácticas de Fabricación Actuales (CGMP); presencia de impurezas de N-nitroso-duloxetina por encima del límite recomendado por la FDA.

<p><b>Producto:</b> Cápsulas de duloxetina de liberación retardada USP, 60 mg <b>NDC:</b> 51991-0748-90 <b>Número de lote:</b> 241069C <b>Fecha de vencimiento:</b> 05/31/2027</p>
--

Hable con su médico antes de dejar de tomar cualquier medicamento. Dejar de tomar un medicamento sin un reemplazo podría tener riesgos para la salud. Su médico puede hablar con usted sobre otras opciones que sean adecuadas para usted.

**[wellpoint.com/nj/medicaid](https://wellpoint.com/nj/medicaid)**

1091152NJMESWLP 05/26

OMHC# 078-25-59

105-CNMCD26062WLPNJ 051426

